Retatrutide Cost vs. Alternatives: What Women Need to Know Before It Hits the Market
Retatrutide is Eli Lilly's triple-hormone GLP-1/GIP/glucagon agonist showing 24% weight loss in trials. Here's how its projected cost stacks up against semaglutide, tirzepatide, and other alternatives for women.
Read clinical review